Immune-suppressive CD4+CD25+FoxP3+ T-reg accumulate in primary and metastatic cancers and can prevent treatment-induced immune responses, therefore T-reg depletion represents a promising therapeutic approach. This evidence concerns the gene CD4 and metastatic malignant neoplasm.